Results 31 to 40 of about 46,383 (210)
AIDS Research and Therapy, 2012 Background Dyslipidaemia and dysglycaemia have been associated with exposure to ritonavir-boosted protease inhibitors. Lopinavir/ritonavir, the most commonly used protease inhibitor in resource-limited settings, often causes dyslipidaemia.
Sinxadi Phumla Z +5 more
doaj +1 more source
Journal of Infection and Public Health, 2021 Background: Lopinavir-ritonavir is a repurposed drug for coronavirus disease-2019 (COVID-19). In this study, a pooled effect of lopinavir-ritonavir on mortality, virological cure, radiological improvement and safety profile in COVID-19 patients has been ...
Tejas K. Patel +5 more
doaj +1 more source
Drug resistance outcomes of long-term ART with tenofovir disoproxil fumarate in the absence of virological monitoring [PDF]
, 2018 Objectives: The resistance profiles of patients receiving long-term ART in sub-Saharan Africa have been poorly described. This study obtained a sensitive assessment of the resistance patterns associated with long-term tenofovir-based ART in a ...
Appiah, Lambert T +9 more
core +3 more sources
Simultaneous determination of plasma lopinavir and ritonavir by chemometrics-assisted spectrophotometry and comparison with HPLC method [PDF]
Maejo International Journal of Science and Technology, 2013 Chemometrics-assisted spectrophotometry for the determination of two protease inhibitors, lopinavir and ritonavir, in plasma was evaluated. A set of calibration mixtures (calibration set) was designed according to central composite design. The UV spectra
Chutima Matayatsuk Phechkrajang
doaj
Atorvastatin therapy in COVID-19 adult inpatients: A double-blind, randomized controlled trial
International Journal of Cardiology: Heart & Vasculature, 2021 Introduction: Efficacious therapies are urgently required to tackle the coronavirus disease 2019 (COVID-19). This trial aims to evaluate the effects of atorvastatin in comparison with standard care for adults hospitalized with COVID-19.
Lotfollah Davoodi +7 more
doaj +1 more source
Clinical impact of double protease inhibitor boosting with Lopinavir/Ritonavir and Amprenavir as part of salvage antiretroviral therapy [PDF]
, 2003 Purpose: Double protease inhibitor (PI) boosting is being explored as a new strategy in salvage antiretroviral (ARV) therapy. However, if a negative drug interaction leads to decreased drug levels of either or both PIs, double PI boosting could lead to ...
Abdurrahman, Z. +10 more
core +2 more sources
Middle East respiratory syndrome coronavirus: current situation and travel-associated concerns [PDF]
, 2016 This article is made available for unrestricted research re-use and secondary analysis in any form or by any means with acknowledgement of the original source.
Al-Tawfiq, Jaffar A. +2 more
core +1 more source
Journal of Infection in Developing Countries, 2021 Severe COVID-19 infection management for a recipient of kidney transplant has debatable prognosis and treatment. We described the case of a COVID-19 infected 70 year old female, previously had renal transplantation in 2017.
Satriyo Dwi Suryantoro +17 more
doaj +1 more source
Southern African Journal of Infectious Diseases, 2020 Background: Currently there is no proven medical treatment for COVID-19. We aimed to determine the factors affecting mortality and changes in clinical and laboratory findings in patients with severe COVID-19 pneumonia treated with lopinavir/ritonavir ...
Omer Ayten, Bengu Saylan
doaj +1 more source
Diagnosis and Management of COVID-19 Disease [PDF]
, 2020 SARS-CoV-2 is a novel coronavirus that was identified in late 2019 as the causative agent of COVID-19 (aka coronavirus disease 2019). On March 11, 2020, the World Health Organization (WHO) declared the world-wide outbreak of COVID-19 a pandemic.
Carlos, Graham +5 more
core +1 more source